Laremid

Loperamide Hydrochloride, the active ingredient in Laremid, is a peripheral μ‑opioid receptor agonist presented as an oral tablet for oral use. It is used to reduce the frequency and urgency of diarrhoea in adults and to manage symptoms of irritable bowel syndrome with diarrhoea.

GNH USA supplies Laremid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Loperamide Hydrochloride acts on the gastrointestinal tract to control excessive bowel movements in several diarrhoeal conditions.

Acute nonspecific diarrhea: reduces stool frequency and improves stool consistency. Chronic diarrhea: helps maintain hydration by slowing intestinal transit. Irritable bowel syndrome with diarrhea: alleviates urgency and abdominal discomfort associated with IBS‑D.

Loperamide Hydrochloride is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Abdominal cramps or discomfort - Constipation or hard stools - Nausea or mild vomiting - Flatulence or bloating - Dizziness or light‑headedness - Headache

Serious or Rare Side Effects: - Severe constipation leading to bowel obstruction - Toxic megacolon, especially in infectious diarrhoea - Allergic reactions such as rash, pruritus, or angioedema - Ileus or paralytic bowel - Cardiac arrhythmias (rare, associated with high plasma levels)

Before using Laremid, consider the following safety measures.

Do not exceed recommended dose: follow prescriber or label instructions. Use caution in hepatic impairment: reduced clearance may increase exposure. Avoid in children under 2 years: risk of severe constipation. Do not use for infectious diarrhoea caused by Clostridioides difficile or invasive bacteria. Consult a physician for ulcerative colitis or inflammatory bowel disease. Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Laremid may interact with other medicines; review the following categories.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may raise loperamide levels. - Concomitant use with other antidiarrheals can cause excessive slowing of gut motility. - Co‑administration with opioids may enhance opioid effects and risk of respiratory depression. - Use with quinidine may increase cardiac risk. - Combining with certain antibiotics (e.g., clarithromycin) may elevate plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin) may reduce efficacy. - Anticholinergic agents may increase constipation. - Sedating antihistamines can augment dizziness. - Digoxin or other cardiac glycosides may require monitoring. - Alcohol consumption may intensify central nervous system effects.